`
`http://registration.akm.ch/einsicht.php?XNMASKEN_ID=300&XNK...
`
`15th Meeting of the European Neurological Society
`18.06.2005 - 22.06.2005
`
`Wednesday, June 22, 2005
`08:00 - 09:30
`
`Poster Session 5
`
`Multiple sclerosis
`
`High-dose interferon beta-1b (500 mcg every-other-day, subcutaneously) treatment in RR MS
`patients. Safety and MRI results of 1-year follow-up
`
` P 565
`
`P. Barbero, A. Pipieri, E. Verdun, M. Bergui, M. Clerico, A. Ricci, L. Giordano, A. Rovera, E. Cartechini, G.
`Giuliani, E. Pucci, E. Montanari, L. Manneschi, L. Durelli (Orbassano, Turin, Macerata, Fidenza, I)
`
`Multiple sclerosis patients treated with glatiramer acetate demonstrate a reduced secretion of the
`cytokines TNF-alpha and IL-6
`
` P 566
`
`M. Dolev, S. Miron, G. Zelig, A. Achiron (Ramat-gan, IL)
`
`Association of two polymorphisms in IL-1 beta and IL-1RA genes with susceptibility for multiple
`sclerosis
`
` P 568
`
`E. Dincic, M. Zivkovic, D. Obradovic, A. Stankovic, D. Alavantic, R. Raicevic (Belgrad, RS)
`
`A new fatigue scale for MS – initial validation
`
`R.J. Mills, C.A. Young (Liverpool, GB)
`
` P 569
`
`sVCAM-1 in MS patients under interferon beta treatment: a surrogate marker for therapy response? P 570
`
`K. Retzlaff, B.S. Kühne, P. Frielingshaus, S. Mannes-Keil, J. Kraus, C.V. Burger, R. Reuß, M. Kaps, P.
`Oschmann (Giessen, Munster, D)
`
`Circadian rhythmicity of cytokines and cytokine receptors in the serum of MS patients
`
` P 572
`
`J. Kraus, A. Kreiling, S. Mannes-Keil, K. Retzlaff, P. Oschmann (Munster, Giessen, D)
`
`Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral
`lymphocytes from multiple sclerosis patients
`
` P 573
`
`M. Ruggieri, C. Avolio, S. Scacco, C. Pica, A. Lia, G.B. Zimatore, S. Papa, P. Livrea, M. Trojano (Bari,
`Foggia, I)
`
`A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy,
`BG00012, in patients with relapsing-remitting multiple sclerosis
`
` P 574
`
`L. Kappos, D. Miller, R. Gold, E. Havrdova, C. Polman, V. Limmroth, G. O'Neill, R. Conaghan (Basle, CH;
`London, GB; Goettingen, D; Prague, CZ; Amsterdam, NL; Essen, D; Cambridge, USA)
`
`A helper dependent adenovirus efficiently delivers bioactive FGF-II to the CNS
`
` P 575
`
`E. Butti, C. Porcheri, A. Bergami, E. Brambilla, A. Cattalini, A. Recchia, A. Stornauiolo, F. Mavilio, G.
`Martino, R. Furlan (Milan, I)
`
`Immunoablation using cyclophosphamide without haematopoietic stem cell rescue for refractory
`multiple sclerosis
`
` P 576
`
`M. Ko, G. Katsamakis, D. Stefoski, J. Shammo, S. Gregory (Chicago, USA)
`
`Magnetic resonance imaging results from SENTINEL: a randomised controlled trial of natalizumab
`and interferon beta-1a in multiple sclerosis
`
` P 577
`
`E. W. Radue, W. Stuart, P.A. Calabresi, C. Confavreux, S. Galetta, R. Rudick, F. Lublin, B. Weinstock-
`Guttman, D. Wynn, F. Lynn, M. Panzara, A. Sandrock for the SENTINEL Investigators
`
`The efficacy of natalizumab add-on therapy in patients with relapsing multiple sclerosis: subgroup
`analyses of SENTINEL
`
` P 578
`
`W. Stuart, P.A. Calabresi, C. Confavreux, S. Galetta, E.W. Radue, R. Rudick, F. Lublin, B. Weinstock-
`Guttman, D. Wynn, F. Lynn, M. Panzara, A. Sandrock for the SENTINEL Investigators
`
`The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year
`results from the AFFIRM study
`
` P 579
`
`E. Fisher, P. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. Miller, J.T. Phillips, C. Polman, F.
`Lublin, G. Giovannoni, A. Wajgt, R. Rudick, F. Lynn, M. Toal, M. Panzara, A. Sandrock for the AFFIRM
`Investigators
`
`1 of 2
`
`1/6/2016 12:01 PM
`
`Page 1 of 2
`
`Biogen Exhibit 2013
`Coalition v. Biogen
`IPR2015-01993
`
`
`
`Abstractverwaltung Congrex
`
`http://registration.akm.ch/einsicht.php?XNMASKEN_ID=300&XNK...
`
`2 of 2
`
`1/6/2016 12:01 PM
`
`Page 2 of 2
`
`